Nicolas Frances - University of Méditerranée Department of Pharmacokinetics, Faculty of Pharmacy EA3286, 27, bd. Jean Moulin 13385 Marseilles Cedex 5 France

基本信息

浏览量：30

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 45 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Mechanistic PKPD Modeling to Describe Cytokine Release Associated with CD3 T-cell Engager Therapies

Apolline Lefevre,Zinnia P. Parra-Guillen, Inaki F. Troconiz, Christophe Boetsch,Nicolas Frances

FRONTIERS IN IMMUNOLOGY (2025)

引用0浏览0WOS引用

A Model-Based Approach to Evaluate Anti-Drug Antibody Impact on Drug Exposure with Biologics: A Case Example with the CD3 T-Cell Bispecific Cibisatamab

Javier Sanchez, Philippe B Pierrillas,Nicolas Frey,Gregor P Lotz,Siv Jönsson,Lena E Friberg,Nicolas Frances

CPT pharmacometrics & systems pharmacologyno. 6 (2025): 1065-1076

引用0浏览0WOS引用

Combining Mathematical Modeling, in Vitro Data and Clinical Target Expression to Support Bispecific Antibody Binding Affinity Selection: a Case Example with FAP-4-1BBL

Javier Sanchez,Christina Claus,Christine McIntyre,Tamara Tanos,Axel Boehnke,Lena E. Friberg,Siv Jonsson,Nicolas Frances

FRONTIERS IN PHARMACOLOGY (2024)

引用0浏览0WOS引用

Characterization of RO7507062, a CD19-Targeting T-Cell Bispecific Antibody (CD19TCB), and Design of Its Ongoing Phase 1 Trial in Systemic Lupus Erythematosus

Florian Kollert, Sarah Robertson, Veit Erpenbeck,Franziska Regenass-Lechner, Remy Hallet, Jason Neale,Cary M. Looney,Nicolas Frances,Celine Marban-Doran, Sophia Fredrika Soehrman Brossard, Laurie Millar, Beki Finch Johannes Sam,Benjamin A. Fisher,Maria Leandro,Thomas Doerner,Christian Klein, Franz Schuler

ARTHRITIS & RHEUMATOLOGY (2024): 4939-4940

引用0浏览0引用

Supplementary Figure S2 from Combining Nonclinical Experiments with Translational PKPD Modeling to Differentiate Erlotinib and Gefitinib

Miro J. Eigenmann,Nicolas Frances,Gerhard Hoffmann,Thierry Lavé,Antje-Christine Walz

openalex（2023）

引用0浏览0引用

Table S1 from Predicting Tumor Killing and T-Cell Activation by T-Cell Bispecific Antibodies As a Function of Target Expression: Combining in Vitro Experiments with Systems Modeling

Arthur J. Van De Vyver,Tina Weinzierl,Miro J. Eigenmann,Nicolas Frances,Sylvia Herter, Regula B. Buser,Jitka Somandin,Sarah Diggelmann,Florian Limani,Thorsten Lehr,Marina Bacac,Antje-Christine Walz

openalex（2023）

引用0浏览0引用

Supplementary Figure S5 from Combining Nonclinical Experiments with Translational PKPD Modeling to Differentiate Erlotinib and Gefitinib

Miro J. Eigenmann,Nicolas Frances,Gerhard Hoffmann,Thierry Lavé,Antje-Christine Walz

crossref（2023）

引用0浏览0引用

Supplementary Figure S1 from Combining Nonclinical Experiments with Translational PKPD Modeling to Differentiate Erlotinib and Gefitinib

Miro J. Eigenmann,Nicolas Frances,Gerhard Hoffmann,Thierry Lavé,Antje-Christine Walz

openalex（2023）

引用0浏览0引用

A Model‐based Approach Leveraging in Vitro Data to Support Dose Selection from the Outset: A Framework for Bispecific Antibodies in Immuno‐oncology

Javier Sanchez,Christina Claus,Rosmarie Albrecht, Brenda C. Gaillard, Joana Marinho,Christine Mcintyre,Tamara Tanos,Axel Boehnke,Lena E. Friberg,Siv Joensson,Nicolas Frances

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGYno. 11 (2023): 1804-1818

引用1浏览0WOS引用

Supplementary Figure S6 from Combining Nonclinical Experiments with Translational PKPD Modeling to Differentiate Erlotinib and Gefitinib

Miro J. Eigenmann,Nicolas Frances,Gerhard Hoffmann,Thierry Lavé,Antje-Christine Walz

openalex（2023）

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn